1. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
by Paul G. Richardson, Robert L. Schlossman, Melissa Alsina, Donna M. Weber, Steven E. Coutre, Cristina Gasparetto, Sutapa Mukhopadhyay, Michael S. Ondovik, Mahmudul Khan, Carole S. Paley, and Sagar Lonial
Blood
Volume 122(14):
October 3, 2013
©2013 by American Society of Hematology

2. Dosing schedule.
Dosing schedule. During treatment phase 1 (cycles 1-8), panobinostat (3×/week), bortezomib (2×/week), and dexamethasone (the day of and after bortezomib) were administered on a 2-weeks-on/1-week-off schedule. Treatment phase 2 (cycles 9+) consisted of 6-week cycles (two 2-weeks-on/1-week-off repeating cycles), with bortezomib and the corresponding dexamethasone reduced to once per week during their scheduled weeks. IV, intravenous.
Paul G. Richardson et al. Blood 2013;122:
©2013 by American Society of Hematology

3. Progression-free survival and overall survival.
Progression-free survival and overall survival. Kaplan-Meier analyses of (A) progression-free survival and (B) overall survival.
Paul G. Richardson et al. Blood 2013;122:
©2013 by American Society of Hematology

4. Platelet count and neurotoxicity over time.
Platelet count and neurotoxicity over time. (A) Average platelet count (%) compared with baseline over time. Error bars represent the standard error of the mean (SEM). (B) Change from baseline in the mean Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity subscale. Scales were completed on day 1 of each cycle and at the end of treatment. Error bars represent the SEM.
Paul G. Richardson et al. Blood 2013;122:
©2013 by American Society of Hematology